This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
by Zacks Equity Research
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs earnings medical pharmaceuticals
MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA
by Zacks Equity Research
Moderna shares sink 10% after FDA issues Refusal-to-File letter for its mRNA-1010 flu vaccine, citing trial design concerns despite no safety flags.
ALKSPositive Net Change MRNAPositive Net Change EXELPositive Net Change CSTLPositive Net Change
biotechs
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
by Zacks Equity Research
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
GSKPositive Net Change GILDPositive Net Change RCUSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
by Zacks Equity Research
Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
MRKPositive Net Change EXELPositive Net Change NTRANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
by Ahan Chakraborty
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
by Kanishka Das
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
SNYNegative Net Change BMRNPositive Net Change FOLDNegative Net Change
biotechs
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
by Kanishka Das
CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
by Zacks Equity Research
Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.
MRKPositive Net Change LLYPositive Net Change VRTXPositive Net Change
biotechs cell-therapy medical pharmaceuticals
Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?
by Ekta Bagri
BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals